WaveMan
WaveMan · Company
RPID · Rapid Micro Biosystems, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RPID Rapid Micro Biosystems (RPID) Insider Trading, Ownership & Congress Trades

Medical Devices · Laboratory analytical instruments · CIK 0001380106
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $3.7K priced

Rapid Micro Biosystems insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for RAPID MICRO BIOSYSTEMS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Wilson John J. Addington
CHIEF OPERATING OFFICER
SELL
2026-03-12 SECtraded 2026-03-11
9,603
$41.5K
-72.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 20, 2026.
  • The trade is 3.0% of the 316,762 shares held after it.
  • 2 other insiders sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF OPERATING OFFICER Wilson John J. Addington sold about $41.5K of RPID on Mar 11, 2026; 2 other insiders sold within 30 days and 13 funds added in the latest 13F quarter.
WIRTJES SEAN M
CHIEF FINANCIAL OFFICER
SELL
2026-03-12 SECtraded 2026-03-11
7,480
$32.3K
-72.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (2 buys, 2 sales), the last on Feb 20, 2026.
  • +29.0% median (+29.0% mean) 90-day return after 2 previous buys.
  • The trade is 1.3% of the 556,194 shares held after it.
  • 2 other insiders sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER WIRTJES SEAN M sold about $32.3K of RPID on Mar 11, 2026; 2 other insiders sold within 30 days and 13 funds added in the latest 13F quarter.
Spignesi Robert G. Jr.
PRESIDENT AND CEO
SELL
2026-03-12 SECtraded 2026-03-10
17,922
$73.7K
-72.4%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (12 buys, 7 sales), the last on Feb 19, 2026.
  • +8.7% median (+12.5% mean) 90-day return after 5 previous buys.
  • The trade is 1.5% of the 1,169,848 shares held after it.
  • 2 other insiders sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Spignesi Robert G. Jr. sold about $73.7K of RPID on Mar 10, 2026; 2 other insiders sold within 30 days and 13 funds added in the latest 13F quarter.
Wilson John J. Addington
CHIEF OPERATING OFFICER
SELL
2026-02-20 SEC
5,403
$21.2K
-80.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 9, 2026.
  • The trade is 1.7% of the 326,365 shares held after it.
  • 4 other insiders sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF OPERATING OFFICER Wilson John J. Addington sold about $21.2K of RPID on Feb 20, 2026; 4 other insiders sold within 30 days and 13 funds added in the latest 13F quarter.
WIRTJES SEAN M
CHIEF FINANCIAL OFFICER
SELL
2026-02-20 SEC
17,254
$67.6K
-80.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Feb 9, 2026.
  • +29.0% median (+29.0% mean) 90-day return after 2 previous buys.
  • The trade is 3.1% of the 563,674 shares held after it.
  • 4 other insiders sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER WIRTJES SEAN M sold about $67.6K of RPID on Feb 20, 2026; 4 other insiders sold within 30 days and 13 funds added in the latest 13F quarter.
60 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 55 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 80% of Medical Devices
Revenue
+19.7% year over year
more than 71% of Medical Devices
Margin
-140.3% net margin
below 82% of Medical Devices
Buybacks
no share repurchases reported
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 2.3 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch RPID

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-71.5%12M
-72%-24%+23%+71%2025-102025-122026-022026-042026-062026-082026-10 2026-01-30 · Longitude Prime Partners, LLC sold $208.8K2026-02-04 · Longitude Venture Partners II, L.P. sold $190.1K2026-02-19 · Spignesi Robert G. Jr. sold $149.1K2026-02-02 · Longitude Prime Partners, LLC sold $116.9K2026-02-03 · Longitude Prime Partners, LLC sold $116.6K2026-03-10 · Spignesi Robert G. Jr. sold $73.7K2026-02-20 · WIRTJES SEAN M sold $67.6K2026-02-09 · Spignesi Robert G. Jr. sold $48.5K2026-03-11 · Wilson John J. Addington sold $41.5K2026-03-11 · WIRTJES SEAN M sold $32.3K2026-01-23 · Longitude Prime Partners, LLC sold $31.4K2026-02-09 · WIRTJES SEAN M sold $22.8K2026-02-20 · Wilson John J. Addington sold $21.2K2026-02-09 · Wilson John J. Addington sold $17.4K2026-07-08 · Wilson John J. Addington filed to sell $17.0K2026-07-01 · Wilson John J. Addington filed to sell $11.0K2026-06-22 · Wilson John J. Addington filed to sell $6.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RPID: institutional holders (13F)

13F holdings, latest reported quarter
Bain Capital Life Sciences Investors, LLC
8,434,560 sh
$14.6M
ARMISTICE CAPITAL, LLC
3,328,000 sh
$5.8M
ABG-WTT Global Life Science Capital Partners GP Ltd
1,848,296 sh
$3.2M
VANGUARD CAPITAL MANAGEMENT LLC
982,034 sh
$1.7M
KHAZANAH NASIONAL BERHAD
566,905 sh
$980.7K

Congress trades in RPID

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RPID planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Wilson John J. Addington
Filed 2026-07-08
$17.0K
Wilson John J. Addington
Filed 2026-07-01
$11.0K
Wilson John J. Addington
Filed 2026-06-22
$6.5K

RPID mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$194.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$13.0K position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Equity ETF
$23.4K position · as of 2026-05-31
0.0%
Fidelity Extended Market Index Fund
$216.8K position · as of 2026-05-31
0.0%
Dimensional U.S. Small Cap ETF
$65.4K position · as of 2026-07-31
0.0%
U.S. MICRO CAP PORTFOLIO
$30.6K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

RPID financials

Revenue growth
+19.7%
XBRL, annual
Net margin
-140.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$35.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-145.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$40.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.08x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-2.09x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-141.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-76.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-100.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$33.6M$28.1M$22.5M$17.1M
Operating income-$47.4M-$49.9M-$56.6M-$63.2M
Net income-$47.1M-$46.9M-$52.5M-$60.8M
EPS (diluted)-1.05-1.08-1.22-1.43
Operating cash flow-$31.1M-$44.2M-$45.1M-$58.5M
Cash$20.0M$16.9M$24.3M$27.1M
Long-term debt$18.9M$0n/a$0
SEC XBRL, fiscal years, as known on 2026-10-27

RPID Stock Sonar score 5/7 axes

Find similar shapesCompare

RPID ranks highest on growth (71st percentile) and risk and compliance (53rd), and lowest on institutional and government (20th), among Medical Devices peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
20
Inputs
  • Return on equity-141.6% · 20 pct, sector of 183
  • Return on assets-76.4% · 23 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-100.0% · 18 pct, sector of 188
Financial health
20
Inputs
  • Debt to equity1.08x · 17 pct, sector of 159
  • Cash flow to debt-2.09x · 23 pct, sector of 150
Growth
71
Inputs
  • Revenue growth, YoY+19.7% · 71 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
20
Inputs
  • Funds adding, latest quarter13 · 20 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
53
Inputs
  • Short interest, % of float+3.6% · 58 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+10.9% · 48 pct, sector of 198
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies